Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2005-05-03
2005-05-03
Carlson, Karen Cochrane (Department: 1653)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S013800, C514S014800, C530S300000, C435S174000, C424S409000, C623S001100
Reexamination Certificate
active
06887847
ABSTRACT:
The invention is directed to peptides having antimicrobial activity (antimicrobial peptides). The antimicrobial peptides of the present invention are analogs of the Lentivirus Lytic Peptide 1 (LLP1) amino acid sequence. The invention is further directed to peptides referred to as the Lytic Base Unit (LBU) peptides derived from the LLP1 analogs, also having antimicrobial activity. In addition, the present invention is also directed to methods of using the peptides in a variety of contexts, including the treatment or prevention of infectious diseases. The antimicrobial LLP1 analog peptides and the LBU peptides (collectively eLLPs) may be highly active under high salt conditions and in biologic fluids. In addition, the eLLPs are effective when presented either in soluble form, or when attached to a solid surface. Furthermore, the peptides of the present invention are selectively active against a wide variety of bacterial pathogens and exhibit minimal toxicity to eukaryotic cells in vitro and in vivo.
REFERENCES:
patent: 5714577 (1998-02-01), Montelaro et al.
patent: 5945507 (1999-08-01), Montelaro et al.
Honig, B. (1999) Protein folding: from the levinthal paradox to structure prediction. J. Mol. Biol. vol. 293, pp. 283-293. Review.*
Kalia, V.et al.(2003) Rational site-directed mutations of the LLP1 and LLP-2 lentivirus lytic peptide domains in the intracytoplasmic tail of human immunodeficiency virus type 1 gp41 . . . , J. Virol. vol. 77, pp. 3634-3646.*
File,TM. “Overview of Resistance in the 1990s”,Chest.115:3S-8S. Mar. 1999 Supplement.
Friedrich et al., “Salt-Resistant Alpha-Helical Cationic Antimicrobial Peptides”,Antimicrobial Agents and Chemotherapy,43: 1542-1548, 1999.
Hancock. R.E., “Host Defence (Cationic) Peptides: What Is Their Future Clinical Potential?”,Drugs,57: 469-473, Adis International Limited, 1999.
Scott, Yan, and Hancock, “Biological Properties of Structurally Related ∀-Helical Cationic Antimicrobial Peptides”,Infection&Immunity,67: 2005-2009, Apr. 1999.
Tencza et al., “Lentivirus-derived antimicrobial peptides: increased potency by sequence engineering and dimerization”,Journal of Antimicrobial Chemotherapy, 44: 33-41, 1999.
Beary et al., “Interruption of T-Cell signal transduction by lentivirus lytic peptides from HIV-1 transmembrane protein”,Journal of Peptide Research,51: 75-79, 1998.
Hwang and Vogel, “Structure-function relationships of antimicrobial peptides”, Biochem. Cell Biol., 76: 235-246, 1998.
Comardelle et al., “A Synthetic Peptide Corresponding to the Carboxy Terminus of Human Immunodeficiency Virus Type 1 Transmembrane Glycoprotein Induces Alterations in the Ionic Permeability ofXenopus laevisOocytes”,AIDS Research&Human Retroviruses,13: No. 17, pp. 1525-1532, 1997.
Ganz and Lehrer, “Antimicrobial peptides of leukocytes”,Current Opinion in Hematology,4: 53-58, 1997.
Tencza et al., “Novel Antimicrobial Peptides Derived from Human Immunodeficiency Virus Type 1 and Other Lentivirus Transmembrane Proteins”,Antimicrobial Agents&Chemotherapy,41: 2394-2398, 1997.
Tencza et al., “Calmodulin-Binding Function of LLP Segments from the HIV Type 1 Transmembrane Protein Is Conserved among Natural Sequence Variants”,AIDS Research&Human Retroviruses,13: No. 3, 263-269, 1997.
Arroyo et al., “Membrane Permeabilization by Different Regions of the Human Immunodeficiency Virus Type 1 Transmembrane Glycoprotein gp41”,J. Virol.69: 4095-4102, 1995.
Tencza et al., “Effect of Amino Acid Substitutions on Calmodulin Binding and Cytolytic Properties of the LLP-1 Peptide Segment of Human Immunodeficiency Virus Type 1 Transmembrane Protein”,Journal of Virology,69: 5199-5202, 1995.
Yuan et al., “Characterization of the Calmodulin Binding Domain of SIV Transmembrane Glycoprotein by NMR and CD Spectroscopy”,Biochemistry,34: 10690-10696, 1995.
Zanetti, Gennaro and Romeo, “Cathelicidins: a novel protein family with a common propregion and a variable C-terminal antimicrobial domain”,FEBS Letters,374:1-5, 1995.
Merrifield et al., “Design and synthesis of antimicrobial peptides”, Antimicrobial Peptides, Ciba Foundation Symposium, , 5-6, 1994.
Moore et al., “Preliminary Experimental Anticancer Activity of Cecropins”,Peptide Research,7:265-269, 1994.
Miller et al., “Identification of a Calmodulin-Binding and Inhibitory Peptide Domain in the HIV-1 Transmembrane Glycoprotein”, 1993,AIDS Research and Human Retroviruses,9: 1057-1066.
Miller et al., “Alterations in Cell Membrane Permeability by the Lentivirus Lytic Peptide (LLP-1) of HIV-1 Transmembrane Protein”,Virology,196: 89-1000, 1993.
Blondelie et al., “Design of Model Amphipathic Peptides Having Potent Anitmicrobial Activities”,Biochemistry,31:12688-12694, 1992.
Srinivas et al., “Membrane Interactions of Synthetic Peptides Corresponding to Amphopathic Helical Segments of the Human Immunodeficiency Virus Type-1 Envelope Glycoprotein”,Journal of Biological Chemistry,267:7121-7127, 1992.
Wild et al., “A synthetic peptide inhibitor of human immunodeficiency virus replication: Correlation between solution structure and viral inhibition”,Proc. Natl. Acad. Sci. USA,89: 10537-10541, 1992.
Fontenot et al., “A Survey of Potential Problems and Quality Control in Peptide Synthesis by the Fluorenylmethoxycarbonyl Procedure”,Peptide Research,4:19-25, 1991.
Miller et al., “A Structural Correlation Between Lentivirus Transmembrane Proteins and Natural Cytolytic Peptides”,AIDS Research&Human Retroviruses,7:511-519, 1991.
Eisenberg and Wesson, “The Most Highly Amphiphilic ∀-Helics Include Two Amino Acid Segments in Human Immunodeficiency Virus Glycoprotein 41”,Biopolymers,29: 171-177, 1990.
Eisenberg et al., “The hydrophobic moment detects periodicity in protein hydrophocity”,Proc. Natl. Acad. Sci. U.S.A.,81:140-144, 1984.
Chou et al., “Prediction of The Secondary Structure of Proteins From Their Amino Acid Sequence”,Adv Enz Relat Areas Mol Bio,47: 45-146, 1978.
Garnier et al., “Analysis of the Accuracy and Implications of Simple Methods for Predicting the Secondary Structure of Globular Proteins”,J. Mol. Biol.,120: 97-120, 1978.
Mietzner Timothy A.
Montelaro Ronald C.
Baker & Botts LLP
Carlson Karen Cochrane
Liu Samuel Wei
University of Pittsburgh
LandOfFree
Virus derived antimicrobial peptides does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Virus derived antimicrobial peptides, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Virus derived antimicrobial peptides will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3415578